Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In a single-center phase 1-2a study, the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel produced high rates of complete remission and was associated with serious but mainly reversible toxic effects in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). METHODS: We conducted a phase 2, single-cohort, 25-center, global study of tisagenlecleucel in pediatric and young adult patients with CD19+ relapsed or refractory B-cell ALL. The primary end point was the overall remission rate (the rate of complete remission or complete remission with incomplete hematologic recovery) within 3 months. RESULTS: For this planned analysis, 75 patients received an infusion of tisagenlecleucel and could be evaluated for efficacy. The overall remission rate within 3 months was 81%, with all patients who had a response to treatment found to be negative for minimal residual disease, as assessed by means of flow cytometry. The rates of event-free survival and overall survival were 73% (95% confidence interval [CI], 60 to 82) and 90% (95% CI, 81 to 95), respectively, at 6 months and 50% (95% CI, 35 to 64) and 76% (95% CI, 63 to 86) at 12 months. The median duration of remission was not reached. Persistence of tisagenlecleucel in the blood was observed for as long as 20 months. Grade 3 or 4 adverse events that were suspected to be related to tisagenlecleucel occurred in 73% of patients. The cytokine release syndrome occurred in 77% of patients, 48% of whom received tocilizumab. Neurologic events occurred in 40% of patients and were managed with supportive care, and no cerebral edema was reported. CONCLUSIONS: In this global study of CAR T-cell therapy, a single infusion of tisagenlecleucel provided durable remission with long-term persistence in pediatric and young adult patients with relapsed or refractory B-cell ALL, with transient high-grade toxic effects. (Funded by Novartis Pharmaceuticals; ClinicalTrials.gov number, NCT02435849 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some immunotherapies have shown promise in this setting, such as dinutuximab administered in combination with cytotoxic therapy in relapsed/refractory neuroblastoma3,4.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“It has been reported that CAR-T cell therapy shows high response rates to B-ALL patients in different age groups [117–119].”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“Any grade 3 or 4 adverse event 19 (25) 33 (44) 8 (11) 4 (6)”
Self-citationLee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Self-citationMilone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197 · cited 2×
“Increase in aspartate aminotransferase 5 (7) 2 (3) — —”
BackgroundSelf-citationGardner, R. A., Finney, O., Annesley, C., Brakke, H., Summers, C., Leger, K., Bleakley, M., Brown, C., Mgebroff, S., Kelly-Spratt, K. S., et al. (2017) · Blood · doi:10.1182/blood-2017-02-769208 · Cited by 1,121
von Stackelberg, A., Locatelli, F., Zugmaier, G., Handgretinger, R., Trippett, T. M., Rizzari, C., Bader, P., O’Brien, M. M., Brethon, B., Bhojwani, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3301 · Cited by 614 · cited 1×
“Decrease in neutrophil count 1 (1) 6 (8) 1 (1) 1 (1)”
Self-citationSabatino, M., Hu, J., Sommariva, M., Gautam, S., Fellowes, V., Hocker, J. D., Dougherty, S., Qin, H., Klebanoff, C. A., Fry, T. J., et al. (2016) · Blood · doi:10.1182/blood-2015-11-683847 · Cited by 383
Cited by
Items 501–600 of 1,024
Neurotoxicity after CTL019 in a pediatric and young adult cohort
Gofshteyn, J. S., Shaw, P. A., Teachey, D. T., Grupp, S. A., Maude, S. L., Banwell, B., Chen, F., Lacey, S. F., Melenhorst, J. J., Edmondson, M. J., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25315 · Cited by 123
“following infusion.(8) Risk factors and neuropathogenesis of these symptoms in children and young adults, however, is not known.”
BackgroundSelf-citationPerspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors
Kosti, P., Maher, J. F., & Arnold, J. N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01104 · Cited by 123
“At several centers, response rates consistently exceeding 80% have been reported in patients with relapsed/ refractory B-cell acute lymphoblastic leukemia (ALL) (7–9) and lymphoma (10).”
BackgroundEngineering switchable and programmable universal CARs for CAR T therapy
Liu, D., Zhao, J., & Song, Y. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0763-0 · Cited by 130
How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma
Cohen, A. D., Raje, N. S., Fowler, J. A., Mezzi, K., Scott, E., & Dhodapkar, M. V. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2111 · Cited by 125
Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart
Ganatra, S., Carver, J. R., Hayek, S. S., Ky, B., Leja, M. J., Lenihan, D. J., Lenneman, C. G., Mousavi, N., Park, J. H., Perales, M., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.049 · Cited by 120
“ELIANA (10) Relapsed or refractory B-cell lymphoblastic leukemia Tisagenlecleucel 58/75 (77.”
BackgroundInfluentialAdvanced biomaterials for cancer immunotherapy
Yang, F., Shi, K. Y., Jia, Y., Hao, Y., Peng, J., & Qian, Z. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0372-z · Cited by 126
Cost of decentralized CAR T‐cell production in an academic nonprofit setting
Ran, T., Eichmüller, S. B., Schmidt, P., & Schlander, M. (2020) · International Journal of Cancer · doi:10.1002/ijc.33156 · Cited by 110
Strati, P., Nastoupil, L. J., Westin, J. R., Fayad, L., Ahmed, S., Fowler, N. H., Hagemeister, F. B., Lee, H. J., Iyer, S. P., Nair, R. K., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002228 · Cited by 122
“Previous therapies, median [range], n 4 [2-15] 4 [2-15] 4 [2-11]”
Immune cartography of macrophage activation syndrome in the COVID-19 era
McGonagle, D., Ramanan, A. V., & Bridgewood, C. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00571-1 · Cited by 123
Leahy, A. B., Devine, K. J., Li, Y., Liu, H., Myers, R. M., DiNofia, A. M., Wray, L., Rheingold, S. R., Callahan, C. A., Baniewicz, D., et al. (2021) · Blood · doi:10.1182/blood.2021012727 · Cited by 118
Self-citationYang, J., He, J., Zhang, X., Li, J., Wang, Z., Zhang, Y., Qiu, L., Wu, Q., Sun, Z., Ye, X., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00694-6 · Cited by 135
“All 25 patients enrolled in our study received the therapy in a timely fashion with next-day manufacturing of the product and a median of 14 days from apheresis driven by 7 days of rapid sterility testing, which is a significant improvement from the median 45 days it takes from receiving the leukapheresis made in the…”
BackgroundMethodSelf-citationShahid, Z., Jain, T., Dioverti, M. V., Pennisi, M., Mikkilineni, L., Kambhampati, S., Shah, N. N., Dadwal, S., Papanicolaou, G. A., Hamadani, M., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.07.018 · Cited by 142
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies
Ai, K., Liu, B., Chen, X., Huang, C., Yang, L., Zhang, W., Weng, J., Du, X., Wu, K., & Lai, P. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01625-7 · Cited by 133
“Moreover, their limited efficacy in solid tumors presents ongoing challenges [4, 5].”
BackgroundCancer biomarkers for targeted therapy
Liu, D. (2019) · Biomarker Research · doi:10.1186/s40364-019-0178-7 · Cited by 120
Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?
Boissel, N., & Baruchel, A. (2018) · Blood · doi:10.1182/blood-2018-02-778530 · Cited by 126
Self-citationJacoby, E., Bielorai, B., Avigdor, A., Itzhaki, O., Hutt, D., Nussboim, V., Meir, A., Kubi, A., Levy, M., Zikich, D., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25274 · Cited by 126
“EM involvement has not been the focus of any clinical reports of CAR T cells, and has disqualified participation in some.(5,10) In contrast to hematologic malignancies, within solid tumors the stromal and Michal J.”
BackgroundResultInfluentialKansagra, A. J., Frey, N. V., Bar, M., Laetsch, T. W., Carpenter, P. A., Savani, B. N., Heslop, H. E., Bollard, C. M., Komanduri, K. V., Gastineau, D. A., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0451-2 · Cited by 127
Self-citationYou Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy
Pfefferle, A., & Huntington, N. D. (2020) · Cancers · doi:10.3390/cancers12030706 · Cited by 113
“ICANS often develop after CRS, with symptoms ranging from encephalopathy to expressive aphasia and seizures, but rare cases of cerebral edema have also been reported [26,34,35].”
BackgroundWorldwide research trends on tumor burden and immunotherapy: a bibliometric analysis
Zhang, L., Zheng, H., Jiang, S., Liu, Y.-G., Zhang, T., Zhang, J., Lü, X., Zhao, H., Sang, X., & Xu, Y. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001022 · Cited by 132
“One of them explored the fi rst FDA approved CAR-T-cell therapy called tisagenlecleucel, to treat refractory B-cell acute lymphoblastic leukemia [52] .”
BackgroundGurney, M. E., Stikvoort, A., Nolan, E., Kirkham-McCarthy, L., Khoruzhenko, S., Shivakumar, R., Zweegman, S., van de Donk, N. W. C. J., Mutis, T., Szegezdi, É., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.271908 · Cited by 123
“approach to cancer immunotherapy in B-cell acute lymphoblastic leukemia and Bcell non-Hodgkin lymphomas.(5,6) While there is considerable interest in applying”
BackgroundTherapeutic potential of CAR T cell in malignancies: A scoping review
Mehrabadi, A. Z., Ranjbar, R., Farzanehpour, M., Shahriary, A., Dorostkar, R., Hamidinejad, M. A., & Ghaleh, H. E. G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112512 · Cited by 124
Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target
Hartupee, C. D., Nagalo, B. M., Chabu, C. Y., Tesfay, M. Z., Coleman‐Barnett, J., West, J. T., & Moaven, O. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1287459 · Cited by 138
“The foundation for effective CAR-T-cell therapies, exempli fi ed by the anti-CD19 drug for B-cell ALL, Tisagenlecleucel, is targeting unique receptor proteins predominantly expressed in cancer cells (164).”
BackgroundInfections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies
Kampouri, E., Little, J. S., Rejeski, K., Manuel, O., Hammond, S. P., & Hill, J. A. (2023) · Transplant Infectious Disease · doi:10.1111/tid.14157 · Cited by 145
Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models
Dai, H., Zhu, C., Huai, Q., Xu, W., Zhu, J., Zhang, X., Zhang, X., Sun, B., Xu, H., Zheng, M., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.01.034 · Cited by 114
Jabbour, E. J., Sasaki, K., Ravandi, F., Huang, X., Short, N. J., Khouri, M., Kebriaei, P., Burger, J. A., Khoury, J. D., Jorgensen, J. L., et al. (2018) · Cancer · doi:10.1002/cncr.31720 · Cited by 114
Recent advances in the treatment of acute lymphoblastic leukemia
Rafei, H., Kantarjian, H. M., & Jabbour, E. J. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1605071 · Cited by 126
“sisted for a median of 168 d (from 20 to 617 d) [121].”
BackgroundSingh, A. P., Zheng, X., Lin‐Schmidt, X., Chen, W., Carpenter, T. J., Zong, A., Wang, W., & Heald, D. (2019) · mAbs · doi:10.1080/19420862.2019.1688616 · Cited by 123
“d N(1)t dt 1⁄4 Ln2 DT N(1)t Kill N(1)t IC 1⁄4 N(1)t 0 ð Þ (6)”
Recent advances in regenerative medicine strategies for cancer treatment
Mansouri, V., Beheshtizadeh, N., Gharibshahian, M., Sabouri, L., Varzandeh, M., & Rezaei, N. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111875 · Cited by 121
Engineering the next generation of CAR-NK immunotherapies
Biederstädt, A., & Rezvani, K. (2021) · International Journal of Hematology · doi:10.1007/s12185-021-03209-4 · Cited by 119
Qi, Y., Zhao, M., Hu, Y., Wang, Y., Li, P., Cao, J., Shi, M., Tan, J., Zhang, M., Xiao, X., et al. (2022) · Blood · doi:10.1182/blood.2021013733 · Cited by 118
The translational challenges of precision oncology
Pich, O., Bailey, C., Watkins, T. B. K., Zaccaria, S., Jamal‐Hanjani, M., & Swanton, C. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.002 · Cited by 123
Saygin, C., Cannova, J., Stock, W., & Muffly, L. S. (2022) · Haematologica · doi:10.3324/haematol.2022.280638 · Cited by 114
Immunotherapy for Glioblastoma: Adoptive T-cell Strategies
Choi, B. D., Maus, M. V., June, C. H., & Sampson, J. H. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1625 · Cited by 121
“Perhaps the most promising T-cell technology in development is the chimeric antigen receptor (CAR), which received accelerated approval for hematologic malignancies in 2017 (5).”
BackgroundSelf-citationWang, T., Tang, Y., Cai, J., Wan, X., Hu, S., Lu, X., Xie, Z., Qiao, X., Jiang, H., Shao, J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01214 · Cited by 130
“01214 1670 Volume 41, Issue 9 Three recent studies showed the safety and feasibility of dual CD19-/CD22-targeted CAR T-cell therapy, but the results were not superior to those of the CD19-CAR T-cell therapy.14-16 Three other studies tested sequential administration of CD19-CAR T cells and CD22-CAR T cells, which yield…”
BackgroundResultInfluentialVairy, S., Lopes Garcia, J., Teira, P., & Bittencourt, H. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s138765 · Cited by 111
“67 In the pilot study, 13/25 patients had cerebral toxicity with self-limiting symptoms and complete resolution without apparent sequelae.”
InfluentialSelf-citationWang, Y., Jiang, H., Luo, H., Sun, Y., Shi, B., Sun, R., & Li, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01691 · Cited by 119
“Although the adoptive transfer of T cells genetically engineered with a chimeric antigen receptor (CAR) has shown great promise as a therapeutic for hematological malignancies (1, 2), limited success has been made in the application of CAR-T cells for the treatment of solid tumors.”
BackgroundpH-Responsive Nanoparticles for Cancer Immunotherapy: A Brief Review
Yan, Y., & Ding, H. (2020) · Nanomaterials · doi:10.3390/nano10081613 · Cited by 120
“In particular, T cells modified with chimeric antigen receptor (CARs) show exceptional immune activity which have been approved for clinical use to treat B cell acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma [14,15].”
BackgroundIrving, M., Lanitis, E., Migliorini, D., Ivics, Z., & Guedan, S. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.173 · Cited by 113
Gargett, T., Ebert, L. M., Truong, N. T., Kollis, P. M., Šediváková, K., Yu, W., Yeo, E. C. F., Wittwer, N. L., Gliddon, B. L., Tea, M. N., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005187 · Cited by 121
Shah, P. D., Huang, A. C. C., Xu, X., Orlowski, R. J., Amaravadi, R. K., Schuchter, L. M., Zhang, P. J., Tchou, J. C., Matlawski, T., Cervini, A., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0486 · Cited by 120
Self-citationZhao, J., Song, Y., & Liu, D. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0705-x · Cited by 124
“Currently, production failure has been reported [49, 85].”
Recent Advances in Allogeneic CAR-T Cells
Kim, D. W., & Cho, J. (2020) · Biomolecules · doi:10.3390/biom10020263 · Cited by 119
“6% (7 of 92) of patients also did not receive Tisagenlecleucel treatment due to death [5].”
BackgroundSanber, K. S., Savani, B. N., & Jain, T. (2021) · British Journal of Haematology · doi:10.1111/bjh.17544 · Cited by 118
“19 Recipient c-retroviral vector Second-generation Acute = 0 CR = 16 (84) ALL CD28z Chronic = 0 Anti-CD19 Maude et al.(48) 46 Recipient Lentiviral vector Second-generation Acute = 0 See notes ALL 41BBz Chronic = 0 Anti-C19 Jain et al.”
BackgroundCAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities
Fischer, J. W., & Bhattarai, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693016 · Cited by 129
Larson, S. M., Walthers, C. M., Ji, B., Ghafouri, S. N., Naparstek, J., Trent, J., Chen, J. M., Roshandell, M., Harris, C. M., Khericha, M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0964 · Cited by 116
Liu, D. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0819-1 · Cited by 121
“Axicabtagene ciloleucel is also approved for LBCL [9].”
BackgroundKansagra, A. J., Frey, N. V., Bar, M., Laetsch, T. W., Carpenter, P. A., Savani, B. N., Heslop, H. E., Bollard, C. M., Komanduri, K. V., Gastineau, D. A., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.12.068 · Cited by 111
“High remission rates were seen in these studies, and GVHD was not a significant treatmentrelated toxicity [2,7,8].”
InfluentialSelf-citationSiglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia
Jetani, H., Navarro‐Bailón, A., Maucher, M., Frenz, S., Verbruggen, C., Yeguas, A., Vídriales, M., González, M., Saborido, J. R., Kraus, S., et al. (2021) · Blood · doi:10.1182/blood.2020009192 · Cited by 118
Ye, Z., Chen, J., Zhao, X., Li, Y., Harmon, J., Huang, C., Chen, J., & Xu, Q. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c01532 · Cited by 113
CAR-T cell potency: from structural elements to vector backbone components
Mazinani, M., & Rahbarizadeh, F. (2022) · Biomarker Research · doi:10.1186/s40364-022-00417-w · Cited by 118
Cytokine-mediated CAR T therapy resistance in AML
Bhagwat, A. S., Torres, L., Shestova, O. E., Shestov, M., Mellors, P. W., Fisher, H. R., Farooki, S., Frost, B. F., Loken, M. R., Gaymon, A. L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03271-5 · Cited by 124
Self-citationCAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
Rodriguez-Marquez, P., Calleja-Cervantes, M. E., Serrano, G., Oliver-Caldes, A., Palacios-Berraquero, M. L., Martin-Mallo, A., Calviño, C., Español-Rego, M., Ceballos, C., Lozano, T., et al. (2022) · Science Advances · doi:10.1126/sciadv.abo0514 · Cited by 109
Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery
Gutgarts, V., Jain, T., Zheng, J., Maloy, M., Ruiz, J. D., Pennisi, M., Jaimes, E. A., Perales, M., & Sathick, J. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.02.012 · Cited by 112
Azoulay, É., Castro, P., Maamar, A., Metaxa, V., de Moraes, A. G., Voigt, L. P., Wallet, F., Klouche, K., Picard, M., Moreau, A., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00060-0 · Cited by 121
Self-citationEngineered T cell therapy for viral and non-viral epithelial cancers
Norberg, S. M., & Hinrichs, C. S. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.016 · Cited by 116
Si, S., & Teachey, D. T. (2020) · PubMed Central · doi:10.2147/tcrm.s223468 · Cited by 135
“Incidence of ICANS is noteworthy, as 30 of 75 (40%) patients in the ELIANA trial, and 65 of 111 (64%) patients in the ZUMA-2 trial (phase 2 KTE-C19 for patients with r/r mantle cell lymphoma) developed symptoms of neurotoxicity.(28,31) Unlike CRS, the underlying pathophysiology of ICANS remains somewhat unclear.”
BackgroundInfluentialMeyran, D., Zhu, J. J., Butler, J., Tantalo, D. G. M., Macdonald, S., Nguyen, T. N., Wang, M., Thio, N., D’Souza, C., Qin, V. M., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abk1900 · Cited by 121
State of the art in CAR T cell therapy for CD19+ B cell malignancies
Frigault, M. J., & Maus, M. V. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129208 · Cited by 114
“The FDA approved the first CAR T cell therapy in August 2017 for relapsed/refractory pediatric and young adult B-ALL up to 25 years of age based on the phase II, global ELIANA study (9).”
BackgroundRewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells
Huang, Y., Si, X., Shao, M., Teng, X., Xiao, G., & Huang, H. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01255-x · Cited by 117
“In contrast, tisagenlecleucel, a 4-1BB/CD3-z CAR-T cell product, persisted in peripheral blood with a median time of 168 days (a range of 20–617 days) [27].”
BackgroundImmunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges
Kunimasa, K., & Goto, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020597 · Cited by 113
Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies
Dannenfelser, R., Allen, G. M., VanderSluis, B., Koegel, A. K., Levinson, S., Stark, S. R., Yao, V., Tadych, A., Troyanskaya, O. G., & Lim, W. A. (2020) · Cell Systems · doi:10.1016/j.cels.2020.08.002 · Cited by 113
“Despite recent clinical success in using engineered T cells to treat hematologic cancers (Maude et al., 2018; Neelapu et al., 2017), a major barrier in expanding their use to solid tumors is the challenge of specific tumor recognition.”
BackgroundLi, S., Wang, X., Yuan, Z., Liu, L., Luo, L., Li, Y., Wu, K., Liu, J., Yang, C., Li, Z., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1271 · Cited by 108
The EBMT/EHA CAR-T Cell Handbook
Kröger, N., Gribben, J. G., Chabannon, C., Yakoub‐Agha, I., & Einsele, H. (2022) · Springer eBooks · doi:10.1007/978-3-030-94353-0 · Cited by 135
den Eynde, A. V., Gehrcken, L., Verhezen, T., Lau, H. W., Hermans, C., Lambrechts, H. A. J., Flieswasser, T., Quatannens, D., Roex, G., Zwaenepoel, K., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01525-w · Cited by 118
Oberley, M. J., Gaynon, P. S., Bhojwani, D., Pulsipher, M. A., Gardner, R. A., Hiemenz, M., Ji, J., Han, J., O’Gorman, M. R. G., Wayne, A. S., et al. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27265 · Cited by 105
“B-ALL relapse, CD19positive Immunophenotype (flow cytometry): CD19 variable (dim tomoderate), CD22 bright, CD10 variable (negative to dim), TdT, CD34, CD38, CD58, HLA-DR bright, CD123; negative for CD24, CD13, CD33, and MPO 46,XY[1]//46,XX[19] (posttransplant chimerism) Positive for a loss of ETV6 (12p13) signal in 20…”
BackgroundSelf-citationWang, Y., Qi, K., Cheng, H., Cao, J., Shi, M., Qiao, J., Yan, Z., Jing, G., Pan, B., Sang, W., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.11.027 · Cited by 110
A High-Throughput Method for Characterizing Novel Chimeric Antigen Receptors in Jurkat Cells
Bloemberg, D., Nguyen, T., MacLean, S., Zafer, A., Gadoury, C., Gurnani, K., Chattopadhyay, A., Ash, J., Lippens, J., Harcus, D., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.01.012 · Cited by 119
Liu, L., Bi, E., Ma, X., Xiong, W., Qian, J., Ye, L., Pan, S., Wang, Q., Xiao, L., Yang, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19672-2 · Cited by 113
Nanomedicines and nanomaterials for cancer therapy: Progress, challenge and perspectives
Jing, Z., Du, Q., Zhang, X., & Zhang, Y. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.137147 · Cited by 112
Self-citationThe Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy
Paucek, R. D., Baltimore, D., & Li, G. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.002 · Cited by 104
Burkhardt, B., & Hermiston, M. L. (2019) · British Journal of Haematology · doi:10.1111/bjh.15793 · Cited by 105
Optimizing Precision Medicine for Public Health
Bilkey, G. A., Burns, B. L., Coles, E. P., Mahede, T., Baynam, G. S., & Nowak, K. J. (2019) · Frontiers in Public Health · doi:10.3389/fpubh.2019.00042 · Cited by 105
Towards Immunotherapy for Pediatric Brain Tumors
Wang, S. S., Bandopadhayay, P., & Jenkins, M. R. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.05.009 · Cited by 106
Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review
Brandt, L. J. B., Barnkob, M. B., Michaels, Y. S., Heiselberg, J., & Barington, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00326 · Cited by 102
Sommer, C., Cheng, H., Nguyen, D., Dettling, D. E., Yeung, Y. A., Sutton, J. E., Hamze, M., Valton, J., Smith, J. N. P., Djuretic, I. M., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.022 · Cited by 108
Tomizawa, D., Miyamura, T., Imamura, T., Watanabe, T., Saito, A. M., Ogawa, A., Takahashi, Y., Hirayama, M., Taki, T., Deguchi, T., et al. (2020) · Blood · doi:10.1182/blood.2019004741 · Cited by 104
GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia
Temesgen, Z., Assi, M., Shweta, F., Vergidis, P. I., Rizza, S. A., Bauer, P. R., Pickering, B. W., Razonable, R. R., Libertin, C. R., Burger, C. D., et al. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.08.038 · Cited by 115
“Days to clinical improvement 5 (1-14) 11 (4-42) .”
Gu, R., Liu, F., Zou, D., Xu, Y., Yang, L., Liu, B., Liu, W., Chen, X., Liu, K., Guo, Y., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00953-8 · Cited by 114
“from our study suggested that 90% of patients achieved CR/CRi within 28 days after the CAR T cell infusion, which accounted for 82% of the fully enrolled 22 patients in an intention-to-treat analysis; these values are comparable to those obtained in the pivotal ELIANA study, which included an overall remission rate of…”
BackgroundResultInfluentialImproving the ability of CAR-T cells to hit solid tumors: Challenges and strategies
Zhang, Z., Wang, T., Wang, X.-F., Zhang, Y., Song, S., & Ma, C. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106036 · Cited by 115
Self-citationGhilardi, G., Chong, E. A., Svoboda, J., Wohlfarth, P., Nasta, S. D., Williamson, S., Landsburg, J. D., Gerson, J. N., Barta, S. K., Pajarillo, R., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.521 · Cited by 107
Signaling pathways in brain tumors and therapeutic interventions
Li, S., Wang, C., Chen, J., Lan, Y., Zhang, W., Kang, Z., Zheng, Y., Zhang, R., Yu, J., & Li, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01260-z · Cited by 110
“CAR-T cells have received FDA approval in diffuse large B cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL).(214,215) The most studied targets of CAR-T in GBM are HER2, EGFRvIII, as well as IL-13αR2, which have already been published in clinical trial results.”
BackgroundProgress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia
Jabbour, E. J., Pui, C., & Kantarjian, H. M. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1915 · Cited by 103
Gene therapy for visual loss: Opportunities and concerns
Lee, J. H., Wang, J.-H., Chen, J., Li, F., Edwards, T. L., Hewitt, A. W., & Liu, G.-S. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.08.003 · Cited by 100
Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy
Shadman, M. S., Gauthier, J., Hay, K. A., Voutsinas, J. M., Milano, F., Li, A., Hirayama, A. V. V., Sorror, M. L., Cherian, S., Chen, X., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000593 · Cited by 110
Callmann, C. E., Cole, L. E., Kusmierz, C. D., Huang, Z. N., Horiuchi, D., & Mirkin, C. A. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005794117 · Cited by 109
Immunotherapy in endometrial cancer: rationale, practice and perspectives
Cao, W., Ma, X., Fischer, J. V., Sun, C., Kong, B., & Zhang, Q. H. (2021) · Biomarker Research · doi:10.1186/s40364-021-00301-z · Cited by 112
Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies
Totzeck, M., Michel, L., Lin, Y., Herrmann, J., & Rassaf, T. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac106 · Cited by 105
“3 However, the lymphocyte suppressive effects of corticosteroids could last longer, particularly with sustained administration (e.g. for ICANS).”
Advances in immunotherapy for glioblastoma multiforme
Mahmoud, A. B., Ajina, R., Aref, S., Darwish, M., Alsayb, M. A., Taher, M., Alsharif, S. T., Hashem, A. M., & Alkayyal, A. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.944452 · Cited by 107
Chimeric antigen receptor T ( CAR‐T ) cells: Novel cell therapy for hematological malignancies
Abbasi, S., Totmaj, M. A., Abbasi, M., Hajazimian, S., Goleij, P., Behroozi, J., Shademan, B., Isazadeh, A., & Baradaran, B. (2022) · Cancer Medicine · doi:10.1002/cam4.5551 · Cited by 111
Nahas, G. R., Komanduri, K. V., Pereira, D. L., Goodman, M. S., Jiménez, A., Beitinjaneh, A., Wang, T. P., & Lekakis, L. J. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1697814 · Cited by 106
“Despite its persistence, tisagenlecleucel seems to be associated with less acute toxicity and persistence of these CAR-T cells is associated with longer periods of hypogammaglobulinemia [10].”
BackgroundDevelopment of CAR-T cell therapies for multiple myeloma
Gagelmann, N., Riecken, K., Wolschke, C., Berger, C., Ayuk, F. A., Fehse, B., & Kröger, N. (2020) · Leukemia · doi:10.1038/s41375-020-0930-x · Cited by 107
“While CAR-T cell therapy directed against CD19 has been approved for acute lymphoblastic leukemia and diffuse-large B cell lymphoma [15, 16], this antigen is not expressed on MM cells [14, 19].”
BackgroundShalabi, H., Sachdev, V., Kulshreshtha, A., Cohen, J. W., Yates, B., Rosing, D. R., Sidenko, S., Delbrook, C., Mackall, C. L., Wiley, B. M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001159 · Cited by 104
Brivio, E., Locatelli, F., López‐Yurda, M., Malone, A., de Heredia, C. D., Bielorai, B., Rössig, C., van der Velden, V. H. J., Ammerlaan, A. C. J., Thano, A., et al. (2020) · Blood · doi:10.1182/blood.2020007848 · Cited by 106
CAR-T cell therapy and infection: a review
Bupha‐Intr, O., Haeusler, G. M., Chee, L. C. Y., Thursky, K., Slavin, M. A., & Teh, B. W. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1855143 · Cited by 111
“Early landmark trials of tisagenlecleucel in refractory ALL reported IFI incidence of 13%, compared to 5% reported in refractory NHL patients treated with axicabtagene ciloleucel [1,3,35,36].”
BackgroundResultMyers, G. D., Verneris, M. R., Goy, A. H., & Maziarz, R. T. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002056 · Cited by 106
Self-citationCytopenia after CAR-T Cell Therapy—A Brief Review of a Complex Problem
Sharma, N., Reagan, P. M., & Liesveld, J. L. (2022) · Cancers · doi:10.3390/cancers14061501 · Cited by 106
“Currently, the USA FDA has approved CAR-T cell therapy with tisagenlecleucel (tisa-cel) for pediatric ALL in children and young adults up to 25 years [6,7], axicabtagene ciloleucel (axi-cel) [1] and lisocabtagene maraleucel (liso-cel) [8] for relapsed and refractory diffuse large B cell lymphoma (DLBCL), axi-cel in re…”
Tocchetti, C. G., Farmakis, D. T., Koop, Y., Andrés, M. S., Couch, L. S., Formisano, L., Ciardiello, F., Pane, F., Au, L., Emmerich, M., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3340 · Cited by 111
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies
Tao, Z., Chyra, Z., Kotulová, J., Celichowski, P., Mihályová, J., Charvátová, S., & Hájek, R. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01193-6 · Cited by 118
“Meanwhile, in R/R CLL, the most common leukemia in adults, the reported CR rates of anti-CD19 CAR-T cell therapy range from 18 to 29%, which are lower than in other B-cell malignancies [2, 5, 7, 10 – 13, 15, 16].”
New Approaches to the Management of Adult Acute Lymphoblastic Leukemia
Bassan, R., Bourquin, J., DeAngelo, D. J., & Chiaretti, S. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.3648 · Cited by 108
“One-year EFS and OS were 50% and 76%, respectively.(60) This led to the approval of tisagenlecleucel (Kymriah), the first CAR”
BackgroundAcharya, U. H., Dhawale, T. M., Yun, S., Jacobson, C. A., Chávez, J. C., Ramos, J., Appelbaum, J., & Maloney, D. G. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1585238 · Cited by 107
“It is not clear if these biomarkers are useful with the different CAR T cell products with the seminal ZUMA-1 study in NHL additionally demonstrating GM-CSF as a potential biomarker for evolving neurotoxicity.”
BackgroundInfluential
Metadata
- Authors
- Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., Qayed, M., De Moerloose, B., Hiramatsu, H., Schlis, K., Davis, K. L., Martin, P. L., Nemecek, E. R., Yanik, G. A., Peters, C., Baruchel, A., Boissel, N., Mechinaud, F., Balduzzi, A., Krueger, J., June, C. H., Levine, B. L., Wood, P., Taran, T., Leung, M., Mueller, K. T., Zhang, Y., Sen, K., Lebwohl, D., Pulsipher, M. A., & Grupp, S. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Oslo University Hospital (NO)
- Hospital Sant Joan de Déu Barcelona (ES)
- University of Minnesota (US)
- Children's Mercy Hospital (US)
- From the Departments of Pediatrics (S.L.M., S.A.G.) and Pathology and Laboratory Medicine (C.H.J., B.L.L.), Perelman School of Medicine, and Abramson Cancer Center (C.H.J., B.L.L.), University of Pennsylvania, and the Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children’s Hospital of Philadelphia (S.L.M., S.A.G.) — all in Philadelphia; the Department of Pediatrics and Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern...
- Royal Children's Hospital (AU)
- University of Southern California (US)
- ORCID
- Maude, Shannon L.
- Laetsch, Theodore W.
- Buechner, Jochen
- Rives, Susana
- Boyer, Michael
- Bittencourt, Henrique
- Bader, Peter
- Verneris, Michael R.
- Stefanski, Heather E.
- Qayed, Muna
- Hiramatsu, Hidefumi
- Davis, Kara L.
- Martin, Paul L.
- Nemecek, Eneida R.
- Yanik, Gregory A.
- Peters, Christina
- Boissel, Nicolas
- Mechinaud, Francoise
- Balduzzi, Adriana
- Krueger, Joerg
- June, Carl H.
- Levine, Bruce L.
- Zhang, Yiyun
- Lebwohl, David
- Pulsipher, Michael A.
- Grupp, Stephan A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-02
- Volume
- 378
- Issue
- 5
- Pages
- 439-448
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5996391
- OpenAlex
- W2787301955
- Cited by
- 5,735
- References
- 24
- Citations by year
- 2026: 573 · 2025: 671 · 2024: 734 · 2023: 730 · 2022: 784 · 2021: 788 · 2020: 706 · 2019: 496 · 2018: 242
- FWCI
- 207.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tisagenlecleucel, CAR T-cell therapy, anti-CD19, B-cell acute lymphoblastic leukemia, relapsed/refractory leukemia, pediatric and young adult patients, complete remission, minimal residual disease, event-free survival, overall survival, cytokine release syndrome, neurological adverse events, CAR T cell persistence, tocilizumab, treatment toxicity
- MeSH terms
- Adolescent, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Female, Humans, Infusions, Intravenous, Male, Receptors, Antigen, T-Cell, Remission Induction, Survival Analysis, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.